Neeta K. Venepalli
Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Neeta K. Venepalli

Hematology | Oncology
840 S Wood St, Ste 820-e Mc 713, 
Chicago, IL 
Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
840 S Wood St, Ste 820-e Mc 713, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Neeta Venepalli is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Venepalli is rated as an Experienced provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). Her top areas of expertise are Anal Cancer, Familial Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma.

Her clinical research consists of co-authoring 20 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

840 S Wood St, Ste 820-e Mc 713, Chicago, IL 60612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: October 10, 2025
Intervention Type: Radiation, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
Phase II Single-arm Study of the Combination of Palbociclib and Cetuximab in KRAS/NRAS/BRAF Wild-type Metastatic Colorectal Cancer
Phase II Single-arm Study of the Combination of Palbociclib and Cetuximab in KRAS/NRAS/BRAF Wild-type Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Cetuximab, Palbociclib
Study Phase: Phase 2
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
Enrollment Status: Terminated
Publish Date: July 26, 2022
Intervention Type: Drug
Study Drugs: MLN0128, MLN0128 (RP2D), Sorafenib
Study Phase: Phase 1/Phase 2
STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing Insulin-like Growth Factor Receptor 1 (IGF-1R)
STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing Insulin-like Growth Factor Receptor 1 (IGF-1R)
Enrollment Status: Completed
Publish Date: August 22, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

20 Total Publications

Obesity's Disparate Impact on COVID-19 Outcomes in Asian American Patients with Cancer.
Obesity's Disparate Impact on COVID-19 Outcomes in Asian American Patients with Cancer.
Journal: medRxiv : the preprint server for health sciences
Published: June 04, 2025
Similar Doctors
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. James A. Wallace
Oncology | Geriatrics | Hematology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. James A. Wallace
Oncology | Geriatrics | Hematology

Primary Healthcare Associates Sc

19550 Governors Hwy 3300, 
Flossmoor, IL 
 (23.3 miles away)
708-915-8660
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Wallace is an Oncologist and a Geriatrics provider in Flossmoor, Illinois. Dr. Wallace is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Pancreatic Cancer, Pancreatoblastoma, and Familial Colorectal Cancer. Dr. Wallace is currently accepting new patients.

Randy S. Rich
Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Randy S. Rich
Hematology | Oncology
Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Randy S. Rich
Hematology | Oncology

Illinois Cancer Specialists

880 W Central Rd, 
Arlington Heights, IL 
 (21.4 miles away)
847-259-4482
Languages Spoken:
English
See accepted insurances

Randy Rich is a Hematologist and an Oncologist in Arlington Heights, Illinois. Dr. Rich is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Familial Pancreatic Cancer, Lung Cancer, Pleuropulmonary Blastoma, Pancreatic Cancer, and Bone Marrow Aspiration.

Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Robert D. Marsh
Oncology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Robert D. Marsh
Oncology
2650 Ridge Ave, Kellogg Cancer Center, 
Evanston, IL 
 (13.4 miles away)
847-570-2112
Languages Spoken:
English, Dutch
See accepted insurances
Accepting New Patients

Robert Marsh is an Oncologist in Evanston, Illinois. Dr. Marsh is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Pancreatic Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Marsh is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Venepalli's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile